Analyst Research

Report Title Price
Provider: New Constructs, LLC
$25.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: S&P Capital IQ Quantitative Report
$127.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Sciclone Pharmaceuticals Inc Reaffirms FY 2013 Guidance


Monday, 1 Apr 2013 04:00pm EDT 

Sciclone Pharmaceuticals Inc announced that for fiscal 2013, it expects revenues between $150 and $155 million and expects non-GAAP earnings per share (EPS) to be between $0.66 and $0.72. SciClone's non-GAAP EPS forecast for 2013 excludes employee stock-based compensation and other expenses described in the Company's reconciliation of GAAP to non-GAAP income, which the Company is not able to reasonably estimate at this time for the full fiscal year. According to I/B/E/S Estimates, analysts are expecting the Company to report revenues of $155 million for fiscal 2013. 

Company Quote

5.04
-0.07 -1.37%
28 Jul 2014